



## SINGAPORE ASSOCIATION OF PHARMACEUTICAL INDUSTRIES

151 Chin Swee Road, #02-13A/14, Manhattan House, Singapore 169876.

T: +65-6738 0966 F: +65-6738 0977 E: [admin@sapi.org.sg](mailto:admin@sapi.org.sg) W: [www.sapi.org.sg](http://www.sapi.org.sg) UEN: S66SS0025J

### **Singapore Association of Pharmaceutical Industries Announces Newly-Elected President and Vice President**

December 1, 2020, SINGAPORE— The Singapore Association of Pharmaceutical Industries (SAPI) today announced that its board of directors has elected Mr Ashish Pal as President of the association, effective immediately. He previously held the position of Vice-President of the association and serves as the Chair of the Public Policy Committee. He replaces outgoing President, Mr Enver Erkan, who has played a leading role in the association for the past three years. In addition, Ms Celine Ting (Managing Director, Eisai Singapore) will now be joined by Mr Guillermo Frydman (Managing Director, Johnson & Johnson Singapore) as a Vice-President of SAPI.

As President of SAPI, Mr Pal will represent SAPI on all matters pertaining to the association and with a focus on fostering collaborations with policy makers, healthcare providers, and patient groups to improve access to innovative medicines and vaccines. Established in 1966, SAPI currently comprises 33 global biopharmaceutical companies in Singapore, employing close to 10,000 people in the country. With a total projected output close to \$22 billion, the industry accounts for a fifth of Singapore’s manufacturing activity and 4 percent of the country’s GDP.

“I thank Enver for his years of commitment to SAPI and for leading the association over the past six months” said SAPI’s Executive Director Christina Teo. “I am confident that Ashish will continue to lead SAPI in pursuit of our mission towards nurturing partnerships with key stakeholders, with a shared vision towards advancing Singapore’s position as a global biopharmaceutical hub and enhancing access to innovative medicines and vaccines.

Ashish is the Managing Director for the Singapore & Malaysia cluster at MSD. He brings extensive global experiences which include the United States and Asia. He also serves as Vice-President of the Pharmaceutical Association of Malaysia.

“SAPI is committed to building sustainable partnerships with the government and key stakeholders across Singapore as we navigate towards a ‘new normal’. I am honoured to take on this role, and look forward to working in close partnership with my colleagues on the board towards enhancing ongoing dialogue with key stakeholders in pursuit of our shared vision of broadening access to innovative medicines and vaccines,” said Mr Pal.

---

For media queries, please contact:

Ms. Christina Teo

Executive Director

Singapore Association of Pharmaceutical Industries

Tel: 6738 0966

Email: [christina.teo@sapi.org.sg](mailto:christina.teo@sapi.org.sg)

## *About SAPI*

Singapore Association of Pharmaceutical Industries (SAPI) was founded in 1966 and was initially known as the Pharmaceutical Trade Association. In 1975, the Association changed its name to encompass a wider spectrum of pharmaceutical related business into the Association—namely the distributors, manufacturers, representative offices and affiliated companies.

Currently, SAPI comprises 41 members of which 33 are global R&D based biopharmaceutical companies in Singapore, with its members employing close to 10,000 people in the country. SAPI aims to make innovative medicine accessible to patients in Singapore. SAPI achieves this through a sustainable and valued partnership with healthcare professionals and providers, government, patient group stakeholders, and a reputation of consistent ethical behavior.